Drug resistant Epilepsy	***Number (percentage, of total unless otherwise specified)***
Total	131
Underwent epilepsy surgery	97 (74%)
Resective surgery	82 (62.6%)
Disconnection	15 (11.5%)
Surgery recommended but parents declined	11 (8.4%)
Evaluated but not felt to be a surgical candidate	6 (4.6%)
Awaiting discussion or surgery	4 (3.1%)
Not referred for surgical assessment	6 (4.6%)
PET scan performed	29 (22.1%)
Invasive monitoring performed	30 (22.9%)
>1 year post surgery follow up	92 (70.2%)
Engel Scale 1 at 1 year follow up	55 – (59.8% of those > 1 year post surgery)
Engel 1-3 at 1 year follow up	76 – (82.6% of those > 1 year post surgery)
Engel Scale 4 at 1 year follow up	16 – (17.4% of those > 1 year post surgery)
Required further epilepsy surgery	13 – (14.1% of those > 1-year post surgery). 1 underwent vagal nerve stimulator implantation
Histology confirmed FCD	68 (70% of surgical cohort); Resection 71.4%, Disconnection 60%, p=0.3762
Histology nondiagnostic	13 (13.4% of surgical cohort)
Engel Scale 1 in those with confirmed FCD	41 (64% of FCD 1 year post surgery)
Engel Scale 1 in those with non-FCD histology	14 (50% of those 1 year post surgery)
FCD Subtypes (% total FCD)	FCD Type 2a - 12 (17.6%) FCD Type 2b - 47 (69.2%) FCD – subtype unknown - 9 (13.2%)
Other Histology (n=29)	Non-diagnostic - 19 Gliosis – 3 Polymicrogyria – 2 Normal – 1 Glioneuronal tumour – 1 Low grade ganglioglioma (NOS) – 1 Hippocampal sclerosis (no FCD) – 1 Pleomorphic xanthoastrocytoma (PXA) – 1

Table 2. Pharmacoresistant and epilepsy surgery patients. *Abbreviations: Focal cortical dysplasia (FCD), Positron emission tomography (PET), Multidisciplinary Team (MDT)*